Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Courtney Follit"'
Autor:
Haijiao Zhang, Samantha Savage, Anna Reister Schultz, Daniel Bottomly, Libbey White, Erik Segerdell, Beth Wilmot, Shannon K. McWeeney, Christopher A. Eide, Tamilla Nechiporuk, Amy Carlos, Rachel Henson, Chenwei Lin, Robert Searles, Hoang Ho, Yee Ling Lam, Richard Sweat, Courtney Follit, Vinay Jain, Evan Lind, Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Jorge Cortes, Robert Collins, Daelynn R. Buelow, Sharyn D. Baker, Brian J. Druker, Jeffrey W. Tyner
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance o
Externí odkaz:
https://doaj.org/article/998f439604e74cef95464ecda676fa5a
Autor:
Chenwei Lin, Anna Reister Schultz, Courtney Follit, Robert H. Collins, Brian J. Druker, Christopher A. Eide, Daelynn R. Buelow, Haijiao Zhang, Yee Ling Lam, Hoang Ho, Hagop M. Kantarjian, Farhad Ravandi, Jorge E. Cortes, Amy S. Carlos, Guillermo Garcia-Manero, Richard S. Sweat, Jeffrey W. Tyner, Vinay K. Jain, Robert P. Searles, Samantha L. Savage, Sharyn D. Baker, Gautam Borthakur, Evan F. Lind, Rachel Henson, Daniel Bottomly, Libbey White, Erik Segerdell, Shannon K. McWeeney, Tamilla Nechiporuk, Beth Wilmot
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and resistance-conferring tyrosine kinase domain mutations. While crenolani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3f5a05aec1da728f1b1774d127f938
https://doaj.org/article/998f439604e74cef95464ecda676fa5a
https://doaj.org/article/998f439604e74cef95464ecda676fa5a